Traduction de «underlying » (Néerlandais → Français) :

1974 on the opening, transfer and merger of retail pharmacies Royal decree of 9 July 1984 on the provision of information and advertising relating to medicines Royal decree of 11 January 1993 determining the conditions under which medicines for human use may be supplied in sample form Royal decree of 7 April 1995 on the provision of information and advertising relating to medicines for human use Royal decree of 15 July 1997 on active implantable medical devices, transposing Directive 90/385 EEC (AIMD) Royal decree of 19 December 1997 on the control and analysis of the raw materials used by dispensing chemists Royal decree of 18 March 1999 on medical devices, transposing Directive 93/42/EEC of 14 June 1993 (MDD) Royal decree of 11 July 2003 determining the conditions under which medicines for veterinary use may be supplied in sample form Law of 16 December 2004 modifying the regulations on combating abuses in the promotion of medicines Royal decree of 10 June 2006 establishing the report point referred to in Article 10, § 5, of the law of 25 March 1964 on medicines Royal decree of 23 November 2006 implementing Article 10, § 3, of the law of 25 March 1964 on medicines Royal decree of 25 February 2007 recognising the institutions referred to in Article 10 § 3 of the law of 25 March 1964 on medicines
1974 on the opening, transfer and merger of retail pharmacies Royal decree of 9 July 1984 on the provision of information and advertising relating to medicines Royal decree of 11 January 1993 determining the conditions under which medicines for human use may be supplied in sample form Royal decree of 7 April 1995 on the provision of information and advertising relating to medicines for human use Royal decree of 15 July 1997 on active implantable medical devices, transposing Directive 90/385 EEC (AIMD) Royal decree of 19 December 1997 on the control and analysis of the raw materials used by dispensing chemists Royal decree of 18 March 1999 on medical devices, transposing Directive 93/42/EEC of 14 June 1993 (MDD) Royal decree of 11 July 2003 determining the conditions under which medicines for veterinary use may be supplied in sample form Law of 16 December 2004 modifying the regulations on combating abuses in the promotion of medicines Royal decree of 10 June 2006 establishing the report point referred to in Article 10, § 5, of the law of 25 March 1964 on medicines Royal decree of 23 November 2006 implementing Article 10, § 3, of the law of 25 March 1964 on medicines Royal decree of 25 February 2007 recognising the institutions referred to in Article 10 § 3 of the law of 25 March 1964 on medicines

Home | Actueel | Progress Under Threat: Perspectives on the HIV treatment gap
Accueil | Actualités | VIH/sida : des avancées en péril - Conséquences des pénuries de traitement dans cinq pays

Drug resistent TB drugs under the microscope (Engels) | Artsen Zonder Grenzen
Drug resistent TB drugs under the microscope (anglais) | Médecins Sans Frontières

Home | Actueel | Drug resistent TB drugs under the microscope (Engels)
Accueil | Actualités | Drug resistent TB drugs under the microscope (anglais)

A modified declaration was provided to members of the Transparency Committee and the Consultative Committee, since members of these committees are representatives of bodies falling under the FAMHP mission.
A modified declaration was provided to members of the Transparency Committee and the Consultative Committee, since members of these committees are representatives of bodies falling under the FAMHP mission.

with the existing Ethics Committees via the Clinical Trial Task Force (CTTF), an informal structure established in 2003 under the FAMHP mission.
with the existing Ethics Committees via the Clinical Trial Task Force (CTTF), an informal structure established in 2003 under the FAMHP mission.

It may formulate advice about any matters relating to the policies being followed or to be pursued by the FAMHP. This committee consists of representatives of patients and users, of all sectors who are involved in the matters under the Agency’s mission, as well as representatives from the relevant federal public services.
It may formulate advice about any matters relating to the policies being followed or to be pursued by the FAMHP. This committee consists of representatives of patients and users, of all sectors who are involved in the matters under the Agency’s mission, as well as representatives from the relevant federal public services.

In the course of 2008 there were at least another 99 early phase trials of which 43 trials being carried out for the first time in humans, 164 phase I trials (including those not falling under the definition of an early phase trial), 176 phase II trials and 223 phase III trials. The database currently does not always allow a distinction to be made between early phase trials as defined above and later phases.
In the course of 2008 there were at least another 99 early phase trials of which 43 trials being carried out for the first time in humans, 164 phase I trials (including those not falling under the definition of an early phase trial), 176 phase II trials and 223 phase III trials. The database currently does not always allow a distinction to be made between early phase trials as defined above and later phases.

A MEDICINES AGENCY UNDER CONSTRUCTION Annual report 2007
A MEDICINES AGENCY UNDER CONSTRUCTION Annual report 2007

This report “The Federal Agency for Medicines and Health Products – 2008 in words and images. Annual Report 2008” was created under the coordination of the Communication Division of the FAMHP.
This report “The Federal Agency for Medicines and Health Products – 2008 in words and images. Annual Report 2008” was created under the coordination of the Communication Division of the FAMHP.